- Company
- Ono Pharma Korea’s Braftovi has been approved in Korea
- by Aug 24, 2021 06:05am
- Ono Pharma Korea announced on the 23rd that it has been approved by the MFDS on the 19th by Braftovi (Encorafenib), a direct bowel cancer treatment. BRAF inhibitor Braftovi can be used as a combination therapy with Erbitux (Cetuximab) in adult patients with direct colon cancer with previous treatment experience and confirmed BRAF V600E mut
- Policy
- The effectiveness of NIP expansion policy?
- by Aug 24, 2021 06:05am
- Moon Jae-in president announced to expand under the age of 17 for vaccine against cervical cancer vaccination for free, while the few people seemed to be criticizing as 'show off'. President Moon said he would expand the vaccination target from the age of 12 to the age of 17 to mark the 4th anniversary of the petition. In the past, peo
- Company
- Will the issue of GLT-2 inhibitors be resolved in 3 years?
- by Eo, Yun-Ho Aug 23, 2021 10:28pm
- Attention is focusing on whether the issue of combined benefits of DPP-4 inhibitors and SGLT-2 inhibitors will finally be solved. According to academia, the HIRA will hold a meeting of experts on September and discuss the combined benefits of oral diabetes treatment DPP-4 inhibitors and SGLT-2 inhibitors. The issue, which has been almost t
- Policy
- Over 40mil COVID-19 vaccines cleared for release in 6 mos
- by Lee, Tak-Sun Aug 23, 2021 05:55am
- The number of COVID-19 vaccines granted National Lot Release in Korea has exceeded 40 million. The large-scale batches of Pfizer vaccines introduced in late July have accelerated the number of vaccines approved for lot release. According to the Ministry of Food and Drug Safety on the 22nd, 1.6 million doses (for 800 thousand people) Pfize
- Policy
- Perjeta's price was down 10% to ₩2,214,600
- by Kim, Jung-Ju Aug 23, 2021 05:55am
- Five drugs that succeeded in insurance benefits in Korea due to Risk Sharing Agreement (RSA) have been re-contracted by lowering drug prices to the expiration of the contract. According to the industry, the MOHW is recently pushing to revise the list of drug benefits aimed at the 1st of next month for a total of five successful drugs negotia
- Company
- Accumulated exports of K-Biosimilars reach ₩9Tril
- by Chon, Seung-Hyun Aug 23, 2021 05:55am
- Cumulative exports of biosimilars developed by Celltrion and Samsung Bioepis exceeded &8361;9 trillion. Growth has slowed compared to the products’ first market entry, however, the products have been marking stable growth based on their solid pipeline. ◆Celltrion Healthcare exports &8361;789.5billion in H1…cumulative sales exceed &83
- Policy
- AstraZeneca vaccine has been approved in 121 countries
- by Lee, Tak-Sun Aug 23, 2021 05:55am
- The most widely approved coronavirus vaccine in countries around the world was AZD1222, co-developed by AstraZeneca and Oxford University. AZ vaccine was the first approved COVID vaccine in Korea in February. According to the MFDS, the KOBIA, abd the national vaccine safety technology support center, AZ vaccine was approved in 121 countries a
- Policy
- Women under the age of 17 will be given Gardasil 9 for free
- by Lee, Jeong-Hwan Aug 23, 2021 05:55am
- President Moon Jae-in is answering directly to celebrate the 4th anniversary of the petition. He promised the government will expand the scope of free cervical cancer vaccinations from women under the current age of 12 to under the age of 17 so that all women and teenagers can receive free vaccination benefits. He said he would also make ef
- Policy
- Lyrica CR generics begin development...PMS expires next July
- by Lee, Tak-Sun Aug 20, 2021 05:56am
- Development for generics of Pfizer’s pain reliever ‘Lyrica CR,’ whose post-market surveillance (PMS) period expires in July next year, has begun. Unlike Lyrica, which is taken twice a day, Lyrica CR is a once-daily formulation and is used for peripheral neuropathic pain in adults. With more than 80 pharmaceutical companies participatin
- Company
- Samsung Bioepis performance rebounds in Q2
- by An, Kyung-Jin Aug 20, 2021 05:56am
- Samsung Bioepis has succeeded in making a performance rebound and overcoming the unfavorable factors from COVID-19. Despite the pandemic, sales of its biosimilars that are being sold globally through overseas partners, have steadily increased to serve as a reliable source of performance. According to the Financial Supervisory Service on the
